PCSK9 inhibitor, preparation method therefor, and use thereof
By developing PCSK9 small molecule inhibitor compounds represented by general formula (I), the problems of existing large molecule inhibitors requiring injection and high cost have been solved, achieving safe and effective oral lipid-lowering effects, reducing LDL-C and Lp(a) levels, and meeting the treatment needs of cardiovascular diseases.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- ZHUHAI UNITED LAB
- Filing Date
- 2026-01-20
- Publication Date
- 2026-07-30
AI Technical Summary
Most existing PCSK9 inhibitors are large molecule drugs that require injection and are expensive. There is a lack of oral PCSK9 small molecule inhibitors, which cannot meet the needs of effective treatment for cardiovascular diseases.
To develop a small molecule inhibitor compound of general formula (I) and its isomers or pharmaceutically acceptable salts that reduce LDL-C levels by binding to the PCSK9 protein for the treatment of cardiovascular disease and hyperlipidemia (a).
This study provides a safe and metabolically beneficial oral PCSK9 small molecule inhibitor that can effectively reduce LDL-C and Lp(a), offering a new approach for the prevention and treatment of cardiovascular diseases.
Smart Images

Figure CN2026073639_30072026_PF_FP_ABST